RNA (Avidity Corp) Earnings per share growth in current year
Avidity Biosciences drug production stability depends on the reliability of external contractors in the US. The year-over-year change in earnings per share reflects efficiency dynamics, where the parameter value equals 4.00. Cash flows remain volatile due to clinical trial costs, although the business is shielded from sanctions and geopolitical pressure.
Financial and market metric breakdowns for Avidity Biosciences (RNA)
- stock price and consensus target price:
- business market valuation indicators:
- book capitalization indicators:
- debt burden and liquidity indicators:
Total Debt to Capital Coefficient Avidity Biosciences|RNA - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio aviditybiosciences.com|RNA - Company Aggregate Debts|Debts to Net Assets Avidity Corp|RNA - Company Long-Term Debts|Short-Term Debt Avidity Biosciences|Immediate Liquidity Ratio aviditybiosciences.com
- earnings and multiples data:
RNA - Net Profit|Future Profit Avidity Biosciences|RNA - P/E Multiple|Projected Price to Earnings Ratio Avidity Corp|RNA - Price/Earnings to Growth Ratio|Total Company Value to Operating Income Before Depreciation Ratio Avidity Corp|RNA - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Avidity Biosciences|RNA - Earnings per share for the last twelve months|Year-over-year earnings per share growth for the last 12 months aviditybiosciences.com|RNA - Earnings growth in current year|Earnings growth forecast for next year Avidity Biosciences
Fundamental valuation:RNA - Avidity Biosciences Inc
This indicator measures the year-over-year dynamics of earnings per share, allowing for an assessment of business capitalization efficiency and the growth rates of its real profitability. By analyzing the year-over-year shift in EPS metrics, an investor can track the impact of Avidity Biosciences (RNA) licensing deals with pharma behemoths on the company's financial stability in the absence of M&A activity.
Direct competitors
Tempus Labs - Earnings per share increase in current year|QGEN (Qiagen Group) - Earnings growth in current year|Earnings per share growth in current year IONS|Earnings growth in current year RGEN|Expected net earnings per share growth this year crisprtx.com|Earnings per share growth in current year GeneDx WGS|Ultragenyx Pharmaceutical Inc. (RARE) - Earnings per share growth rate in current year|BEAM - Earnings per share growth in current year|Expected net earnings per share growth this year Sarepta Corp SRPT|TWST: Earnings growth in current year|Net earnings per share growth this year 10xgenomics.com|NTLA (Intellia Therapeutics, Inc.) - Earnings growth in current year|Stoke Therapeutics Inc (STOK) - Expected net earnings per share growth this year|Earnings growth in current year BLFS|WVE - Earnings per share growth rate in current year|Earnings per share growth in current year Maze Therapeutics Inc MAZE|SION: Earnings per share growth this year|Prime Medicine - Earnings growth in current year|Taysha Gene Therapies Inc (TSHA) - Net earnings per share growth this year|QURE: Earnings growth in current year|Earnings per share growth rate in current year MeiraGTx Corp (MGTX)|Earnings per share growth in current year REGENXBIO Inc.|solidbio.com (SLDB) - Expected net earnings per share growth this year|Earnings per share growth in current year Ocugen (OCGN)|PACB (Pacific Biosciences of California, Inc.) - Earnings per share increase in current year|Earnings per share growth in current year Benitec BNTC|DSGN: Earnings per share growth this year|Rocket Pharmaceuticals - Earnings growth in current year|FDMT - Earnings growth in current year|LXEO: Earnings growth in current year|Earnings per share growth this year KRRO|Earnings per share growth in current year Editas|Earnings per share growth this year SLN (Silence Therapeutics Corp)|Earnings growth in current year PRQR|Earnings growth in current year codexis.com (CDXS)|Earnings growth in current year SGMO (Sangamo Therapeutics, Inc.)|Earnings growth in current year Nautilus Biotechnology, Inc. NAUT|MGX: Net earnings per share growth this year|DTIL: Earnings per share growth in current year|GBIO: Earnings growth in current year|BOLD - Expected net earnings per share growth this year|XCUR (Exicure Inc.) - Earnings growth in current year|Earnings per share growth this year IMNN (Celsion Corporation)|Earnings growth in current year PHIO|Expected net earnings per share growth this year mustangbio.com|TransCode Therapeutics, Inc. - Net earnings per share growth this year|Net earnings per one share growth for the current year BNGO (Bionano Genomics Inc.)|APDN: Net earnings per share growth this year|Earnings per share growth rate in current year bluebird bio Inc.|IPA (immunoprecise.com) - Net earnings per share growth this year|Omega Therapeutics Corp - Earnings per share increase in current year|OMIC (Singular Genomics Systems) - Earnings growth in current year|Earnings per share growth in current year RGLS|Earnings growth in current year SYRS|Expected net earnings per share growth this year Telesis Bio Inc.|Earnings per share growth in current year TRACON TCON|Unity Biotechnology, Inc (UBX) - Earnings per share growth rate in current year
